

## Glenmark receives tentative ANDA approval for generic Zytiga

23 January 2019 | News

**Glenmark's current portfolio consists of 148 products authorized for distribution in the U.S. marketplace and 54 ANDA's pending approval with the U.S. FDA**



Glenmark Pharmaceuticals Inc., USA (Glenmark) has been granted tentative approval by the United States Food & Drug Administration (U.S. FDA) for Abiraterone Acetate Tablets USP, 250 mg, a generic version of Zytiga®1 Tablets, 250 mg, of Janssen Biotech, Inc.

According to IQVIA™ sales data for the 12 month period ending November 2018, the Zytiga® Tablets, 250 mg market2 achieved annual sales of approximately \$1.3 billion.

Glenmark's current portfolio consists of 148 products authorized for distribution in the U.S. marketplace and 54 ANDA's pending approval with the U.S. FDA.